THDBH101

THDBH101 is an investigational small molecule dual inhibitor of sodium-glucose cotransporter 2 (SGLT2) and urate anion exchanger 1 (URAT1), developed by Dongbao Zixing (Hangzhou) Biopharmaceutical, a subsidiary of Tonghua Dongbao Pharmaceutical. It is primarily being developed for the treatment of type 2 diabetes mellitus (T2DM) and associated metabolic conditions such as hyperuricemia and gout. By inhibiting SGLT2 in the kidneys, THDBH101 reduces renal glucose reabsorption and promotes urinary glucose excretion, thereby lowering blood glucose levels in an insulin-independent manner. Simultaneously, its inhibition of URAT1 reduces the reabsorption of uric acid in the proximal tubule, facilitating its excretion and lowering serum uric acid levels. This dual mechanism of action is particularly beneficial for diabetic patients who often suffer from comorbid hyperuricemia. THDBH101 is currently undergoing clinical evaluation to establish its safety and efficacy profiles.